<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78872">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833546</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200592-002</org_study_id>
    <nct_id>NCT01833546</nct_id>
  </id_info>
  <brief_title>A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer</brief_title>
  <official_title>A Japanese Single Center, Open-label, Phase I Trial of TH-302 Given Intravenously to Subjects With Solid Tumors as Monotherapy or to Subjects With Advanced Pancreatic Cancer in Combination With Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Japanese Phase 1, open-label, and dose-escalating trial of TH-302 as monotherapy
      in subjects with solid tumors and  in  combination  with  gemcitabine  in  subjects with
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects experiencing Dose Limiting Toxicity</measure>
    <time_frame>Time Frame: up to Day 28 of Cycle 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Treatment-emergent adverse events</measure>
    <time_frame>Baseline up to Day 30 after the last dose of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status score</measure>
    <time_frame>Baseline, Day 1 of each cycle up to Day 14 after the last dose of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with best overall response</measure>
    <time_frame>Baseline, Day 1 of Cycle 2, 3, 4 and thereafter Day 1 of every cycle, up to Day 30 after the last dose of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with disease control</measure>
    <time_frame>Baseline, Day 1 of Cycle 2, 3, 4 and thereafter Day 1 of every cycle, up to Day 30 after the last dose of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute levels of tumor markers such as carbohydrate antigen 19-9 (CA 19-9)</measure>
    <time_frame>Baseline, Day 1 of each cycle up to Day 14 after the last dose of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>TH-302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 plus Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 monotherapy</intervention_name>
    <description>TH-302 will be administered weekly at a dose ranging from 240-480 milligram per square meter (mg/m^2) as intravenous infusion over 30 or 60 minutes on Day 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>TH-302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302</intervention_name>
    <description>TH-302 will be administered weekly at a dose of either 240 or 340 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>TH-302 plus Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered weekly at a dose of 1000 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>TH-302 plus Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 20 years of age

          -  Signed written informed consent form

          -  Histologically or cytologically confirmed advanced or metastatic solid tumor
             previously treated with one or more standard treatment regimen(s) or for which no
             effective therapy is available

          -  Histologically or cytologically confirmed locally advanced unresectable or metastatic
             pancreatic adenocarcinoma previously untreated with chemotherapy or systemic therapy

          -  Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Acceptable liver function, renal function, hematologic status and coagulation status
             as defined in the protocol

          -  No clinically significant abnormalities in urinalysis

          -  Effective contraception for both male and female subjects if the risk of conception
             exists

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  Prior anti-cancer treatment with more than 3 myelosuppressive cytotoxic chemotherapy
             regimens

          -  Prior treatment with gemcitabine for their advanced or metastatic pancreatic cancer,
             except for radiosensitizing doses of gemcitabine

          -  Prior radiotherapy to more than 30 percent of the bone marrow within 6 months prior
             to the trial entry

          -  Cardiac disease with New York Heart Association (NYHA) Class 3 or 4, within 6 months
             prior to the trial entry

          -  Clinically significant (that is, active) cardiovascular disease

          -  Seizure disorders requiring anticonvulsant therapy

          -  Known brain, leptomeningeal or epidural metastases (unless previously treated and
             well controlled for at least 3 months at the trial entry)

          -  Previously treated malignancies other than the current disease for at least 5 years
             at the trial entry

          -  Severe chronic obstructive or other pulmonary disease major surgery, within 4 weeks
             prior to the trial entry, without complete recovery

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

          -  Anti-cancer treatment prior to trial entry

          -  Participation in an investigational drug or device trial within 4 weeks prior to the
             trial entry

          -  Known infection with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C

          -  A history of allergic reactions

          -  Taking a medication that is either moderate or strong inhibitor or inducer of
             cytochrome P450 (CYP)3A4 or is a sensitive substrate of other cytochrome P450

          -  Pregnancy or lactation period

          -  Concomitant disease or condition that could interfere with the conduct of the trial,
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the
             subject in this trial

          -  Unwillingness or inability to comply with the trial protocol for any reason

          -  Legal incapacity or limited legal capacity

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono Co., Ltd., Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>TH-302</keyword>
  <keyword>gemcitabine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
